However breast cancer cells harboring PIK3CA mutations are selectively sensitive to mTOR allosteric and kinase inhibitors but not in breast cancer cells with loss of PTEN, suggesting that the functional consequences of these two mechanisms of mTOR activation are quite distinct [26]. Here, PTEN is linked to breast cancer.